Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction
Status:
Recruiting
Trial end date:
2024-12-15
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the relationship between NT-proBNP and empagliflozin effects in
patients with chronic heart failure with mildly reduced ejection fraction (HFmrEF 41-49%) and
reduced ejection fraction (HFrEF ≤40%) whether diabetic or non-diabetic patients.